Latest News

Germany lagging behind in stem cell research

Neural stem cell. Confocal microscopy image illustrating long-range organization for neurons (green) and nuclei (blue) within a developing neural construct. © University of Wisconsin, Photo: Michael Schwartz.


by tg

A new analysis comparing the amount of funding invested into stem cell research clearly demonstrates declining investment in Germany. In contrast, the US, the UK, Sweden and Japan have increased their investments into the future field.

According to a White Paper from experts of the German Stem Cell Network (GSCN), investments into stem cell research in Germany initially increased from €58.8m in 2009 to €71.3m in 2011 but then permanently decreased to €54.9m by 2014. In contrast, the UK government almost doubled the amount of money into stem cell research from €82.4m in the fiscal year 2010/11 to €169.2m in 2014/15. Whilst investments of the Japanese funding bodies remained constant (€65.1m) from 2009-2012, they rose to €91.2m in 2014 due to the new focus of government investment into applications of induced pluripotent cells (iPSCs).

Most funding, however, is available in the US: the NIH has increased its annual budget for stem cell research from €1,070m in 2011 to €1.400m in 2015. However, funding of the state of New York and the Californian CIRM added €40.5m and €270m annually from 2011-2015 to that amount, respectively.

The GSCN said that Germany ranked last in funding with €0.68/citizen behind Japan (0.72), Sweden (1.02), the UK (2.62), and the US (4.36). The European Federation of Pharmaceutical Industry Associations (EFPIA) and the European Commission have put a focus on creating stem cell resources for secondary drug screening within the Innovative Medicines Initiative. They underline the need for improved funding to exploit the potential of stem cells in drug screening and regenerative medicine.

SARS-CoV-2-antibodies may promote severe COVID-19

According to a new study by Willianne Hoepel and colleagues from Amsterdam UMC, serum taken from patients with severe COVID-19 had an increased level...

BioVersys gets €20m EIB loan to develop novel antibiotics

The venture debt loan is financed under the Infectious Diseases Finance Facility set up as part of Horizon 2020, the European Union’s research and...

B.1.1.7 variant associated with higher mortality

Previous reports from British autorities that suggested a 30 to 100% higher mortality of B.1.1.7 than of the previously dominant form in Europe are...

EMA: AZD1222 causes serious rare ADEs

However, the EMA has no idea which component of the cheapest COVID-19 vaccine on the market is supposed to cause the splanchnic leg and sinus vein...

EU approves Biontech/Pfizer vaccine for adolescents

The decision theoretically extends the reach of the vaccine, which is approved in the EU for use in uninfected individuals over the age of 16....

USA supports to temporarily waive IP of COVID-19 vaccines

The initiative, which South Africa and India have been pushing before the World Trade Organisation since last autumn and which was rejected by the...

Novel COVID antibody enters clinical testing

In contrast to existing COVID-19 treatments, the safety design of COR-101 is optimised for the treatment of hospitalized COVID-19 patients with...